Dec 19, 2006
Announcement of Additional Details Concerning the Issue of Shares to GlaxoSmithKline

Dec 19, 2006
GlaxoSmithKline and Genmab Enter Global Agreement for HuMax-CD20

Dec 15, 2006
Genmab Announces AMG 714 Development Update

Dec 13, 2006
Grant of Warrants in Genmab A/S

Dec 13, 2006
Genmab Announces HuMax-ZP3 Cancer Program

Dec 11, 2006
Genmab Announces Additional Positive Results In HuMax-CD20 CLL Phase I/II Study

Dec 11, 2006
Genmab Initiates HuMax-CD20 Front Line CLL Study

Dec 10, 2006
Genmab Announces Early Results of Ongoing HuMax-CD4 Trials

Dec 5, 2006
Genmab Announces Positive Interim Data for the HuMax-CD20 Phase II RA Study

Dec 5, 2006
Genmab’s Partner Roche Identifies Disease Areas Addressed in Collaboration

Dec 4, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Nov 21, 2006
Genmab to Present at Piper Jaffray 18th Annual Health Care Conference

Nov 20, 2006
Genmab Licenses MIF Receptor Target from Cytokine PharmaSciences

Nov 8, 2006
Roche Presents Positive Preclinical Data on Genmab Antibody

Nov 3, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Oct 31, 2006
Genmab Announces Results for the First Nine Months of 2006

Oct 24, 2006
Genmab Initiates Combination Study of HuMax-EGFr with Chemo-Radiation

Oct 18, 2006
Genmab hosts Research, Development and Business Update

Sep 22, 2006
Genmab Completes Accrual in HuMax-CD20 Phase II RA Study

Sep 20, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Sep 20, 2006
Grant of Warrants in Genmab A/S

Sep 14, 2006
Genmab Initiates HuMax-EGFr Pivotal Study in Refractory Head and Neck Cancer

Sep 7, 2006
Genmab to Present at Three Investor Conferences in September

Aug 22, 2006
Genmab Announces 2006 First Half Year Results

Aug 22, 2006
Interim Report For the 6 months ended June 30, 2006

Aug 2, 2006
Genmab Named Finalist for European Biotechnica Award 2006

Jul 28, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Jul 10, 2006
Genmab Initiates HuMax-CD20 Pivotal Study in NHL

Jul 5, 2006
Genmab Named Finalist for Investor Relations Excellence Award

Jun 22, 2006
Corrected AMG 714 Phase II Results

Jun 22, 2006
AMG 714 Phase II Results Presented at EULAR Conference

Jun 22, 2006
Grant of Warrants in Genmab A/S

Jun 21, 2006
Grant of Warrants in Genmab A/S

Jun 21, 2006
Grant of Warrants in Genmab A/S

Jun 12, 2006
Genmab to Present at Two Investor Conferences

Jun 8, 2006
HuMax-CD38 Shows Unique Property in Preclinical Studies

May 30, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

May 23, 2006
Genmab Initiates HuMax-CD20 CLL Pivotal Study

May 16, 2006
AMG 714 Data to be Presented at EULAR Conference

May 2, 2006
Genmab Announces 2006 First Quarter Results

Apr 25, 2006
Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees

Apr 25, 2006
Passing of Genmab A/S' Annual General Meeting

Apr 6, 2006
Annual Report 2005

Apr 5, 2006
Genmab A/S Summons Annual General Meeting

Mar 21, 2006
Genmab Reports ACR50 and ACR70 Results in HuMax-CD20 Study to Treat RA

Mar 10, 2006
Genmab Announces Update on AMG714 Program with Amgen

Mar 8, 2006
77% Achieve ACR20 with Genmab’s HuMax-CD20 in Rheumatoid Arthritis Study

Mar 8, 2006
Genmab to Present at Lehman Brothers’ Ninth Annual Global Healthcare Conference

Mar 3, 2006
Clarification of Stock Exchange Notice No. 10 of March 2, 2006

Mar 2, 2006
Grant of Warrants in Genmab A/S

Mar 2, 2006
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Feb 27, 2006
Genmab Reaches First Milestone in HuMax-TAC Agreement with Serono

Feb 16, 2006
Genmab Announces Year End 2005 Financial Results

Feb 16, 2006
Preliminary Annual Report 2005

Feb 13, 2006
Genmab Licenses Angiogenesis Targets from Bionomics

Jan 31, 2006
Genmab’s Financial Calendar for 2006

Jan 27, 2006
Genmab Announces Over-Allotment Option Fully Exercised

Jan 27, 2006
Genmab Announces the Placing of its Private Placement

Jan 12, 2006
Genmab Announces Private Placement Memorandum in Connection With a Private Placement

Jan 3, 2006
Genmab's HuMax-EGFr Awarded Fast Track Status from FDA